BMC Cancer

1. WANG T, Wang X, Wu J, Li X, et al
   Causal relationship between thyroid dysfunction and ovarian cancer: a two-sample Mendelian randomization study.
   BMC Cancer. 2024;24:629.
   

   >> Share

   
   
2. LI C, Cui Q, Wang X, Yao S, et al
   CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
   BMC Cancer. 2024;24:609.
   

   >> Share

   
   

   
   Curr Treat Options Oncol

3. WANG JY, Gross M, Urban RR, Jorge S, et al
   Correction to: Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
   Curr Treat Options Oncol. 2024 May 18. doi: 10.1007/s11864-024-01216.
   

   >> Share

   
   

   
   Eur J Obstet Gynecol Reprod Biol

4. GAO Y, Zang L, Ye Y, Ma F, et al
   Immunotherapy combined with targeted therapy in advanced small cell carcinoma of the ovary of hypercalcemic type: A case of overall survival lasting for over 5 years.
   Eur J Obstet Gynecol Reprod Biol. 2024 Apr 6:S0301-2115(24)00168.
   

   >> Share

   
   

   
   Gynecol Oncol

5. LARAJA A, Connor Y, Poulson MR
   The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
   Gynecol Oncol. 2024;187:163-169.
   

   >> Share

   
   
6. ZENATRI M, Perennec T, Michon C, Gernier F, et al
   Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
   Gynecol Oncol. 2024;187:139-144.
   

   >> Share

   
   

   
   Int J Cancer

7. CHAO X, Kai Z, Wu H, Wang J, et al
   Fragmentomics features of ovarian cancer.
   Int J Cancer. 2024 May 20. doi: 10.1002/ijc.34981.
   

   >> Share

   
   

   
   Int J Gynaecol Obstet

8. BORELLA F, Bertero L, Valabrega G, Fucina S, et al
   Response: Comment on searching for prognostic markers for stage I epithelial ovarian cancer: A role for systemic inflammatory markers.
   Int J Gynaecol Obstet. 2024 May 20. doi: 10.1002/ijgo.15595.
   

   >> Share

   
   

   
   J Clin Oncol

9. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
   Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
   J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
   

   >> Share

   
   

   
   Nat Med

10. FRIEDMAN CF, Manning-Geist BL, Zhou Q, Soumerai T, et al
    Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
    Nat Med. 2024;30:1330-1338.
    

    >> Share

    
    

    
    Obstet Gynecol

11. SONG BB, Anderson ZS, Masjedi AD, Lee MW, et al
    Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer.
    Obstet Gynecol. 2024 May 23. doi: 10.1097/AOG.0000000000005530.
    

    >> Share

    
    

    
    Oncology (Williston Park)

12. LEWIS CR, Uchic-Boccella J, Zimmerman J, Miller E, et al
    Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis.
    Oncology (Williston Park). 2024;38:191-193.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share